Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
1(50.0%)
N/A
1(50.0%)
2Total
Phase 4(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03373552Active Not Recruiting

Genetic Polymorphism Associated With Coronary Heart Disease Susceptibility and Variability of Clopidogrel Response

Role: lead

NCT04982341Completed

HFNC and Prone Positioning in Awake Patients With Severe COVID-19

Role: lead

NCT04348227Unknown

How COVID-19 Virus Outbreak Affects Antimicrobial Resistance in a Low-middle-income Country's ICU?

Role: lead

NCT04259073Not ApplicableCompleted

Does Pregabalin Improve Post-operative Pain After C-section Delivery

Role: lead

NCT03981081Phase 4Unknown

Prednisone Reduction in ICU Patients With COPD Exacerbation

Role: lead

All 5 trials loaded